Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of ampicillin and gentamicin is a standard-of-care antibiotic regimen used for the pre-emptive treatment of suspected early-onset sepsis in neonates. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while gentamicin is an aminoglycoside that inhibits protein synthesis by binding to the 30S ribosomal subunit. This specific combination is the focus of a Phase 2 clinical trial led by the University of Florida (NCT04112667) titled "Antibiotic Effects on the Developing Microbiome in Preterm Neonates." The study evaluates the impact of pre-emptive postnatal antibiotic exposure versus no pre-emptive antibiotics on the gut microbiome assembly, metabolic profiles, and clinical morbidities such as necrotizing enterocolitis (NEC) and late-onset sepsis in preterm infants born at less than 33 weeks gestation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + gentamicin (University of Florida).